|
Jun 30
|
BofA Remains Bullish on Argenx (ARGX) With a Buy Rating and $804 PT
|
|
Jun 30
|
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
|
|
Jun 26
|
High Growth Tech Stocks In Europe To Watch June 2025
|
|
Jun 3
|
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
|
|
May 29
|
Argenx added to Best Ideas List at Wedbush
|
|
May 28
|
argenx Announces Results of Annual General Meeting of Shareholders
|
|
May 28
|
Argenx Set to See Further Growth Due to Vyvgart Momentum, Pipeline Expansion, Wedbush Says
|
|
Apr 11
|
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting
|
|
Apr 11
|
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
|
|
Apr 11
|
Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug
|
|
Apr 10
|
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
|
|
Apr 10
|
argenx SE (ARGX): Among the Aggressive Stocks Picked by Hedge Funds
|
|
Apr 8
|
Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients
|
|
Apr 8
|
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
|
|
Mar 4
|
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
|
|
Feb 28
|
Argenx's Q4 Sales Backed by Vyvgart's Growth, Oppenheimer Says
|
|
Feb 28
|
Exploring 3 High Growth Tech Stocks in Europe
|
|
Feb 27
|
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
|
|
Feb 21
|
These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50
|
|
Feb 20
|
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
|